Cefepime/sulbactam
| Combination of | |
|---|---|
| Cefepime | Cephalosporin |
| Sulbactam | β-Lactamase inhibitor |
| Clinical data | |
| Trade names | Maxictam-AF |
| Legal status | |
| Legal status |
|
Cefepime/sulbactam is a 1:1 fixed-dose combination of cefepime (a fourth-generation cephalosporin[1]) and sulbactam (a β-lactamase inhibitor). The combination exerts a bactericidal effect by disrupting bacterial cell wall synthesis through transpeptidase inhibition, thereby impairing peptidoglycan cross-linking.[2] It was developed in 2006 by Russian researchers.[3]
Cefepime/sulbactam was approved for medical use in Russia in 2019[3] and is also registered in Belarus, Armenia, Azerbaijan, Uzbekistan, Kyrgyzstan and Mongolia under the trade name Maxictam-AF.[4]
- ^ "List of Fourth generation cephalosporins".
- ^ Wareham DW, Momin MH, Phee LM, Hornsey M, Standing JF (2020-01-01). "Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infections". The Journal of Antimicrobial Chemotherapy. 75 (1): 135–139. doi:10.1093/jac/dkz420. ISSN 1460-2091. PMID 31617905.
- ^ a b Yakovlev SV, Suvorova MP, Bykov AO (2021). Cefepime/Sulbactam — A New Innovative Antibiotic for In-Hospital Treatment of Severe Infections and the Implementation of Carbapenem-Replacement Strategy to Contain Antibiotic Resistance. Antibiotics and Chemotherapy. Vol. 66. pp. 82–98. doi:10.37489/0235-2990-2021-66-3-4-82-98.
- ^ "Максиктам-АФ – ГРЛС: Справочник РУ – Государственный реестр лекарственных средств".